1207760-89-1

Basic information

• Product Name: 2-{[1-(2-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]thio}-4-(2-methoxyethoxy)-N-(4-methyl-1,3-thiazol-2-yl)butanamide
• Synonyms: 2-{[1-(2-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]thio}-4-(2-methoxyethoxy)-N-(4-methyl-1,3-thiazol-2-yl)butanamide
• CAS NO: 1207760-89-1
• Molecular Weight: 519.048
• Mol File: 1207760-89-1.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-{[1-(2-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]thio}-4-(2-methoxyethoxy)-N-(4-methyl-1,3-thiazol-2-yl)butanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{[1-(2-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]thio}-4-(2-methoxyethoxy)-N-(4-methyl-1,3-thiazol-2-yl)butanamide(1207760-89-1)
• EPA Substance Registry System: 2-{[1-(2-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]thio}-4-(2-methoxyethoxy)-N-(4-methyl-1,3-thiazol-2-yl)butanamide(1207760-89-1)

Safety Data

• Hazardous Substances Data: 1207760-89-1(Hazardous Substances Data)

Upstream product

• 792953-14-1 5-amino-1-(2-chloro-phenyl)-1H-pyrazole-4-carboxylic acid amide 
• 61072-66-0 2-bromo-4-(2-methoxyethoxy)butanoic acid 
• 1006597-09-6 1-(2-chloro-phenyl)-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one 
• 64096-89-5 5-amino-1-(2-chlorophenyl)-1H-pyrazole-4-carbonitrile 
• 10449-07-7 (2-chlorophenyl)hydrazine 
• 1082528-89-9 1-(2-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidine-4-thiol 
• 1207760-90-4 2-bromo-4-(2-methoxyethoxy)-N-(4-methyl-1,3-thiazol-2-yl)butanamide 

Relevant articles and documents

The discovery of a novel series of glucokinase activators based on a pyrazolopyrimidine scaffold

Glucokinase is a key enzyme in glucose homeostasis since it phosphorylates glucose to give glucose-6-phosphate, which is the first step in glycolysis. GK activators have been proven to lower blood-glucose, and therefore have potential as treatments for type 2 diabetes. Here the discovery of pyrazolopyrimidine GKAs is reported. An original singleton hit from a high-throughput screen with micromolar levels of potency was optimised to give compounds with nanomolar activities. Key steps in this success were the introduction of an extra side-chain, which increased potency, and changing the linking functionality from a thioether to an ether, which led to improved potency and lipophilic ligand efficiency. This also led to more stable compounds with improved profiles in biological assays.